Status:
COMPLETED
RAS Quantification in Patients With Aliskiren or Candesartan
Lead Sponsor:
Medical University of Vienna
Conditions:
Hypertension
Chronic Kidney Disease
Eligibility:
All Genders
18-99 years
Phase:
PHASE4
Brief Summary
Forced blockade of the renin-angiotensin-system (RAS) by using direct renin inhibition (DRI) has long been propagated to effectuate beneficial outcomes. However, recent large clinical trials have outl...
Eligibility Criteria
Inclusion
- Chronic kidney disease stages III-IV (defined by modification of diet in renal disease (MDRD) formula)
- Urinary albumin to creatinine ratio (UACR) \>300mg/g, UACR \>200mg/g if already receiving RAS blockade
- Arterial hypertension
Exclusion
- Age \<18 years
- Diabetes mellitus type 2 (defined by WHO criteria)
- Chronic kidney disease stage V (end-stage renal disease)
- UACR \>3500mg/g
- Severe hypertension (systolic blood pressure \>180mmHg)
- Pregnancy
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2016
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01827202
Start Date
December 1 2012
End Date
February 1 2016
Last Update
March 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical University of Vienna, Department of Internal Medicine III, Division of Nephrology and Dialysis
Vienna, Vienna, Austria, 1090